Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration

Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is limited in clinical use due to the drug resistance, poor brain targeting, and side effects. Temozolomide hexadecyl ester (TMZ16e), a TMZ derivative with high lipophilicity, membrane permeability, and high anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Siqi, Yu, Yawen, Wang, Aiping, Duan, Xinliu, Sun, Yuchen, Wang, Liangxiao, Chu, Liuxiang, Lv, Yanan, Cui, Nan, Fan, Xuesong, Sha, Chunjie, Xu, Lixiao, Sun, Kaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429944/
https://www.ncbi.nlm.nih.gov/pubmed/36059989
http://dx.doi.org/10.3389/fphar.2022.965789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429944/
https://www.ncbi.nlm.nih.gov/pubmed/36059989
http://dx.doi.org/10.3389/fphar.2022.965789

Ejemplares similares